hBD3-3 M1

General Information


DRACP ID  DRACP01164

Peptide Name   hBD3-3 M1

Sequence  GKCSTRGRKCMRRKK

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Not available

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
hBCSCs (human Breast Cancer Stem cells, Celprogen, USA;positive for CD44) human Breast Cancer Stem cells Carcinoma As show in fig3 Western blot analysis assay Not available Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01164

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C70H135N31O18S3

Absent amino acids  ADEFHILNPQVWY

Common amino acids  KR

Mass  204510

Pl  12.12

Basic residues  8

Acidic residues  0

Hydrophobic residues  0

Net charge  8

Boman Index  -8106

Hydrophobicity  -193.33

Aliphatic Index  0

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  125

Absorbance 280nm  8.93

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID EP3111951B1

Patent Title  Anticancer Functional Peptide for the Treatment of Breast Cancer

Other Iinformation  Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status: Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019

Other Published ID  EP3111951A4  EP3111951B1  ES2773755T3  KR101693533B1  KR20160115314A  US2017042963A1  US9993519B2  WO2016153185A1 




DRACP is developed by Dr.Zheng's team.